Sterile Fill Finish:

Market Insight, CDMO Pricing and Competitor Benchmarking

Over 700 cumulative hours of qualitative and quantitative data collection and analysis have been utilized to update Nice Insight’s Sterile Fill Finish: Market Insight, CDMO Pricing and Competitor Benchmarking study.

About This Report

• We have continued our pricing study and updated the pricing for 2024. We now offer a unique perspective as we can comment on trends in sterile injectable manufacturing since 2022.

• We provide projections for ongoing growth of therapeutics entering the clinic and expecting approval, which will drive the need for manufacturing and analytical services.

• We survey the regulatory, technical, and clinical challenges encountered by innovators and manufacturers in this burgeoning market.

• We obtained input from subject matter experts (SMEs) from contract development and manufacturing service providers and buyers of outsourced services.

• We put the manufacturing market in context of ongoing geopolitical news.  

Study Methodology

Nice Insight has compiled primary and secondary data to provide a view on the continued success of sterile injectable drugs, including those formulated using novel delivery technologies, and their development, manufacturing, and commercialization. Sources include market research reports, published articles, and interviews with industry experts. References are provided at the end of the report.

• Throughout the report, both specific pieces of information and overall assessments based on sets of collected data are presented. References are provided where specific information is listed. In many cases, the references contain additional insights that might be of interest to the reader.

• For the latest edition of Nice Insight’s Sterile Fill Finish: Market Insight, CDMO Pricing and Competitor Benchmarking study we have focused only on the sterile injectable CDMO market. We updated all of our trends sections with up-to-date primary, proprietary data and a survey of secondary data from the published literature and industry databases to create a comprehensive landscape of outsourced sterile injectables manufacturing. 

• A team comprising six Ph.D.-level experts collaborated with a group of 25+ existing clients representing CDMOs within the sterile injectable manufacturing and development sector to probe and better understand benchmarks, current challenges, and the future of the industry.

• Our staff with over 45 years of industry experience worked for over four months to advise on big-picture trends shaping the industry and to unify the data into a holistic view.

• Individual interviews were performed with SMEs representing leadership, manufacturing, innovators, and other operations at small and midsized CDMOs to discuss pricing for contract development and manufacturing services.